Tolvaptan for the Treatment of Enlarged Polycystic Liver Disease

Publisher： Karger

E-ISSN： 2296-9705|7|2|108-111

ISSN： 2296-9705

Source： Case Reports in Nephrology and Dialysis, Vol.7, Iss.2, 2017-07, pp. : 108-111

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease

By  

American Journal of Nephrology, Vol. 45, Iss. 3, 2017-02 ,pp. : 257-266

Karger

Access to resources Recommend Favorite

Two Enlarged Kidneys: A Manifestation of Erdheim-Chester Disease

By  

American Journal of Nephrology, Vol. 21, Iss. 4, 2001-08 ,pp. : 315-317

Karger

Access to resources Recommend Favorite

Hemoperfusion Treatment in a Septic Shock Patient with Autosomal Dominant Polycystic Kidney Disease and Increased HMGB1 Protein Levels

By  

Blood Purification, Vol. 32, Iss. 2, 2011-06 ,pp. : 139-142

Karger

Access to resources Recommend Favorite

Autosomal Dominant Polycystic Kidney Disease: New Treatment Options and How to Test Their Efficacy

By  

Kidney and Blood Pressure Research, Vol. 32, Iss. 5, 2009-11 ,pp. : 380-387

Karger

Access to resources Recommend Favorite

A Patient with Autosomal Dominant Polycystic Kidney Disease Undergoing CAPD Complicated by Intracystic Hemorrhage: Successful Treatment by Alcohol Sclerotherapy

By  

Nephron, Vol. 86, Iss. 3, 2000-11 ,pp. : 362-363

Karger

Access to resources Recommend Favorite